

THERAPEUTICS FOR COVID-19TUESDAY 6th -
THURSDAY 8th OCTOBER 2020

(12.00 - 16.00 GMT DAILY)



Antiviral Group

PROGRAMME

TUESDAY 6 OCTOBER

DAILY START TIMES:

8.00am US EASTERN • 1.00pm LONDON • 8.00pm CHINA CENTRAL TIME

PROGRAMME – NOTE THE TIMINGS BELOW ARE IN GMT

12.00 - 12.05

WELCOMEALAN HAY Francis Crick Institute, London, UK &
FREDERICK HAYDEN University of Virginia School of Medicine,
Charlottesville, VA, USA

12.05 - 12.20

OPENING REMARKS

JEREMY FARRAR Wellcome Trust, London, UK

12.20 - 14.05

SESSION 1 (PLENARY)Co-Chairs: BIN CAO China-Japan Friendship Hospital, Beijing, China &
MARIA ZAMBON PHE, London, UK

12.20 - 12.45

COVID-19 CLINICAL SPECTRUM, COMPLICATIONS, AND COINFECTIONS

BIN CAO China-Japan Friendship Hospital, Beijing, China

12.45 - 13.05

VIRAL REPLICATION KINETICS AND ANTIBODY RESPONSES

MALIK PEIRIS University of Hong Kong, HK SAR, China

13.05 - 13.25

PATHOLOGICAL FINDINGS IN COVID-19 AUTOPSY

XIU-WU BIAN Third Military Medical University, Chongqing, China

13.25 - 13.45

IMMUNOPATHOGENESIS OF COVID-19

PETER OPENSHAW Imperial College London, UK

13.45 - 14.05

PATHOGENESIS AND MANAGEMENT OF ARDS

RICHARD WUNDERINK Northwestern University, Chicago, IL, USA

14.05 - 14.15

COMFORT BREAK

14.15 - 15.50

SESSION 2 (ORAL ABSTRACT SESSION 1)Co-Chairs: JOHN BEIGEL NIAID, Bethesda, MD, USA &
ALAN HAY Francis Crick Institute, London, UK

14.20 - 14.35

SOFOSBUVIR AND DACLATASVIR COMPARED TO STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH CORONAVIRUS INFECTION (COVID-19): A RANDOMISED CONTROLLED TRIAL

ANDREW HILL University of Liverpool, Liverpool, UK

14.35 - 14.50

INHIBITION OF SIRTUINS IS BROADLY EFFECTIVE AGAINST CORONAVIRUSES

LIUDI TANG Evrys Bio, LLC, Doylestown, PA, USA

14.50 - 15.05

SAFETY AND EFFICACY OF INHALED SNG001 (IFN-β1A FOR NEBULISATION) FOR THE TREATMENT OF PATIENTS WITH CONFIRMED SARS-COV-2 INFECTION: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PILOT TRIAL

TOM WILKINSON University of Southampton, Southampton, UK

15.05 - 15.20

REPURPOSING OF CLINICALLY-APPROVED DRUGS FOR THE TREATMENT OF COVID-19

KRIS WHITE Icahn School of Medicine at Mount Sinai, New York, NY, USA

15.20 - 15.35

SAFETY AND TOLERABILITY OF LANADELUMAB, A PLASMA KALLIKREIN INHIBITOR, IN SUBJECTS HOSPITALIZED WITH COVID-19-RELATED PNEUMONIA: PHASE 1B STUDY DESIGN

DAN SEXTON Takeda Pharmaceutical Company Ltd, Lexington, MA, USA

15.35 - 15.50

FLUVOXAMINE FOR PREVENTION OF CLINICAL DETERIORATION IN EARLY COVID-19: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL

ANGELA M REIERSSEN Washington University School of Medicine, St. Louis, MO, USA

15.50 - 15.55

CLOSE OF DAY ONE**POSTER VIEWING**

(Located in the Poster Area on the conferencing platform)

WEDNESDAY 7 OCTOBER

DAILY START TIMES:

8.00am US EASTERN • 1.00pm LONDON • 8.00pm CHINA CENTRAL TIME

PROGRAMME – NOTE THE TIMINGS BELOW ARE IN GMT

12.00 - 13.50

SESSION 3 (PLENARY)Co-Chairs: MICHAEL ISON Northwestern University, Chicago, IL, USA &
HUI-LING YEN University of Hong Kong, HK SAR, China

12.05 - 12.25

SARS-COV-2 ANTIVIRAL TARGETS

MARK DENISON Vanderbilt University Medical Center, Nashville, TN, USA

12.25 - 12.45

PRE-CLINICAL MODELS FOR DOWNSELECTING CANDIDATESANDRES PIZZORNO International Center for Research in Infectious Diseases,
Lyon, France

12.45 - 13.05

CONVALESCENT PLASMA AND POLYCLONAL ANTIBODIES

MICHAEL JOYNER Mayo Clinic, Rochester, MN, USA

13.05 - 13.25

MONOCLONAL ANTIBODIES

ERICA SAPHIRE La Jolla Institute for Immunology, CA, USA

13.25 - 13.50

RECOVERY TRIAL AND STRATEGIES FOR RAPID CLINICAL TESTING

PETER HORBY University of Oxford, Oxford, UK

13.50 - 14.00

COMFORT BREAK

14.00 - 15.35

SESSION 4 (ORAL ABSTRACT SESSION 2)Co-Chairs: ANDRES PIZZORNO International Center for Research in Infectious
Diseases, Lyon, France &
ERICA SAPHIRE La Jolla Institute for Immunology, CA, USA

14.05 - 14.20

COMPLETE MAPPING OF MUTATIONS TO THE SARS-COV-2 SPIKE RECEPTOR-BINDING DOMAIN THAT ESCAPE ANTIBODY RECOGNITION

ALLISON GREANEY Fred Hutchinson Cancer Research Center, Seattle, WA, USA

14.20 - 14.35

BLOCKAGE OF CATHEPSIN L ACTIVITY BY SLV213, A NOVEL CYSTEINE PROTEASE INHIBITOR, PREVENTS SARS-COV-2 VIRAL ENTRY

FELIX FRUEH Selva Therapeutics, San Diego, CA, USA

14.35 - 14.50

EFFECT OF JAK INHIBITOR TREATMENT ON CLINICAL OUTCOME, LUNG PATHOLOGY, AND VIRAL LOAD IN A MOUSE MODEL OF PATHOGENIC SARS-COV-2 INFECTION

VICTORIA BAXTER University of North Carolina at Chapel Hill, NC, USA

14.50 - 15.05

TREATMENT OF SEVERE COVID-19 WITH LOW-DOSE SELINEXOR: DEMONSTRATION OF ANTI-VIRAL AND ANTI-INFLAMMATORY ACTIVITIES IN A RANDOMIZED, INTERNATIONAL, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL

GEORGE GEILS Roper St Francis Healthcare, Charleston, SC, USA

15.05 - 15.20

MARGINAL EFFECT OF GC-376 AS A SARS-COV-2 ANTIVIRAL IN THE K18 hACE2 TRANSGENIC MOUSE MODEL

C. JOAQUIN CACERES University of Georgia, Athens, Georgia, USA

15.20 - 15.35

A PHASE 2 STUDY OF LERONLIMAB FOR MILD TO MODERATE CORONAVIRUS DISEASE 2019 (COVID-19)

HARISH SEETHAMRAJU Montefiore Medical Center, Bronx, NY, USA

15.35 - 15.40

CLOSE OF DAY TWO**POSTER VIEWING**

(Located in the Poster Area on the conferencing platform)

THURSDAY 8 OCTOBER

DAILY START TIMES:

8.00am US EASTERN • 1.00pm LONDON • 8.00pm CHINA CENTRAL TIME

PROGRAMME – NOTE THE TIMINGS BELOW ARE IN GMT

12.00 - 12.45

SESSION 5 (PLENARY)Co-Chairs: KIM ARMSTRONG BARDA, Washington DC, USA &
FREDERICK HAYDEN University of Virginia School of Medicine,
Charlottesville, VA, USA

12.00 - 12.20

LESSONS FROM MERSYASEEN ARABI King Saud Bin Abdulaziz University for Health Sciences, Riyadh,
Kingdom of Saudi Arabia

12.20 - 12.45

SOLIDARITY TRIAL & LESSONS LEARNED

MARIE-PIERRE PREZIOSI WHO, Geneva, Switzerland

12.45 - 14.10

SESSION 6 (CLINICAL TRIALS UPDATES)Co-Chairs: KIM ARMSTRONG BARDA, Washington DC, USA &
FREDERICK HAYDEN University of Virginia School of Medicine,
Charlottesville, VA, USA

12.45 - 12.50

INTRODUCTION

12.50 - 13.05

REMEDESIVIR

ANU OSINUSI Gilead, Foster City, CA, USA

13.05 - 13.20

EIDD-2801

WENDY PAINTER Ridgeback Biotherapeutics LP, Miami, FL, USA

13.20 - 13.35

FAVIPIRIVIR

YOHEI DOI University of Pittsburgh, PA, USA

13.35 - 13.50

JAK INHIBITORS

JOHN BEIGEL NIAID, Bethesda, MD, USA

13.50 - 14.05

TOCILIZUMAB IN COVID 19 - UPDATE

LARRY TSAI Genentech, S. San Francisco, CA, USA

14.05 - 14.10

SUMMARY

14.10 - 14.20

COMFORT BREAK

14.20 - 15.30

SESSION 7 (PLENARY)Co-Chairs: MICHAEL ISON Northwestern University, Chicago, IL, USA &
MARCO CAVALERI European Medicines Agency, Amsterdam,
Netherlands

14.20 - 14.45

OPERATION WARP SPEED THERAPEUTICS DEVELOPMENT

JANET WOODCOCK CDER, FDA, Washington DC, USA

14.45 - 15.05

DISCUSSION ON CLINICAL TRIAL ENDPOINTSModerated by MICHAEL ISON Northwestern University, Chicago, IL, USA &
MARCO CAVALERI European Medicines Agency, Amsterdam, Netherlands

15.05 - 15.30

WHO UPDATE ON COVID-19 CLINICAL MANAGEMENT

JANET DIAZ WHO, Geneva, Switzerland

15.30 - 15.45

CLOSE OF CONFERENCE